Posted by Michael Wonder on 19 Aug 2023
EMA accepts Leo Pharma’s marketing authorisation application for delgocitinib cream in chronic hand eczema
18 August 2023 - Leo Pharma is developing delgocitinib cream for the treatment of moderate to severe chronic hand eczema, a hard to treat disease where there is a high unmet medical need for treatment.
Leo Pharma announces today that the EMA has validated the marketing authorisation application for delgocitinib cream, an investigational product and topical pan-Janus kinase inhibitor for the treatment of adult patients with moderate to severe chronic hand eczema.
